RE: Summary29 Apr 2020 09:54
So much going on with DDDD. They're at the forefront of a whole new class of drugs which have almost limitless applications.
The Company has six clinical studies in progress:
* A Phase II clinical study of BLAUTIX(R) in Irritable Bowel Syndrome (IBS).
* A Phase I/II study of MRx0518 in combination with KEYTRUDA(R) (pembrolizumab) in solid tumours.
* A Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours.
* A Phase I study of MRx0518 in patients with pancreatic cancer
* A Phase I/II study of MRx-4DP0004 in asthma.
* A Phase II study of MRx-4DP0004 in patients with COVID-19.
Plus, Preclinical-stage programmes include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions.
Plus, The Company has a research collaboration and option to license agreement with MSD (the tradename of Merck & Co., Inc, Kenilworth, NJ USA), to discover and develop LBPs for vaccines.
Plus they own the largest intellectual property estate in the field (over 400 granted patents).
Plus they own their own commercial scale production facilities